EMA Authorised: Amifampridine SERB (amifampridine phosphate) — SERB SA

View source ↗

Summary

European Medicines Agency authorises amifampridine phosphate (SERB) for various neuromuscular and autoimmune conditions, with Lambert-Eaton Myasthenic Syndrome …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Diseases of the Nervous System
• Cancer
• Immune System Diseases
• Lambert-eaton Myasthenic Syndrome
• Neoplasms
• Nervous System Diseases
• Nervous System Neoplasms
• Neurodegenerative Diseases
• Neuromuscular Diseases
• Neuromuscular Junction Diseases
• Paraneoplastic Syndromes of the Nervous System

Drugs mentioned

• Amifampridine phosphate (amifampridine phosphate)

Snippet

Status: Authorised. Therapeutic area: Lambert-Eaton Myasthenic Syndrome;Paraneoplastic Syndromes, Nervous System;Nervous System Neoplasms;Paraneoplastic Syndromes;Nervous System Diseases;Autoimmune Diseases of the Nervous System;Neurodegenerative Diseases;Neuromuscular Diseases;Neuromuscular Junction Diseases;Immune System Diseases;Autoimmune Diseases;Autoimmune Diseases of the Nervous System;Cancer;Neoplasms. MAH: SERB SA. Decision date: 19/05/2022